UBS Group Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $288.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective hoisted by UBS Group from $253.00 to $288.00 in a report issued on Friday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on the stock. Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an overweight rating in a research report on Tuesday, June 25th. Stifel Nicolaus boosted their price objective on shares of Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a buy rating in a report on Thursday. HC Wainwright restated a buy rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. TD Cowen lifted their price target on Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a buy rating in a research report on Tuesday, June 25th. Finally, BMO Capital Markets reissued an outperform rating and issued a $234.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Eight investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $247.09.

Alnylam Pharmaceuticals Trading Down 1.6 %

Shares of ALNY opened at $243.00 on Friday. The firm has a market cap of $30.74 billion, a PE ratio of -90.67 and a beta of 0.30. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $252.87. The stock has a fifty day moving average price of $159.86 and a 200-day moving average price of $164.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The business had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same quarter last year, the business posted ($1.40) earnings per share. The company’s quarterly revenue was up 54.8% compared to the same quarter last year. As a group, research analysts forecast that Alnylam Pharmaceuticals will post -3.92 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now directly owns 80,534 shares in the company, valued at approximately $18,602,548.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the completion of the transaction, the director now directly owns 136 shares in the company, valued at $30,013.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,301 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the sale, the chief executive officer now owns 80,534 shares in the company, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. Over the last quarter, insiders sold 67,357 shares of company stock worth $13,436,711. Company insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its stake in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Quent Capital LLC boosted its stake in shares of Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 123 shares during the last quarter. Anchor Investment Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $38,000. Altitude Crest Partners Inc. acquired a new position in Alnylam Pharmaceuticals in the 1st quarter valued at $30,000. Finally, GAMMA Investing LLC purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.